Biocon shares rise 2% after USFDA approval for osteoporosis and bone loss drugs
Shares of Biocon Ltd rose 2% to Rs 361.25 on the BSE after its subsidiary, Biocon Biologics, received U.S. FDA approval for two denosumab biosimilars, Bosaya and Aukelso. The regulator also granted provisional interchangeability for both drugs, allowing pharmacy-level substitution, which could (...)
Site référencé: The Economic Times
The Economic Times
Concurrent Gainers : 9 midcap stocks that gain for 5 days in a row
20/09/2025
Concurrent Gainers : 9 midcap stocks that gain for 5 days in a row
20/09/2025
How Jefferies’ Chris Wood tweaked his portfolio after removing RIL. Check full list of stocks
20/09/2025
How Jefferies’ Chris Wood tweaked his portfolio after removing RIL. Check full list of stocks
20/09/2025
Crypto custody startup BitGo reveals near fourfold revenue jump in US IPO filing
20/09/2025
Top 7 flexi cap mutual funds to invest in September 2025
20/09/2025
